Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
BMS will charge same price in UK as its does in US for Cobenfy
Bristol Myers Squibb will offer schizophrenia drug Cobenfy in the U.K. for the same annual list price that it charges in the U.S., the company said.
Kevin Dunleavy
Sep 22, 2025 12:05pm
Teva’s CEO shares ‘Pivot to Growth’ progress
Jun 27, 2025 9:00am
Bristol Myers CEO stays bullish on Cobenfy despite trial flop
Jun 12, 2025 12:43pm
Teva forecasts $5B-plus in innovative drug sales by 2030
May 30, 2025 7:20am
BMS accentuates the positive after Cobenfy trial flop
Apr 24, 2025 11:31am
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Apr 23, 2025 10:35am
